New cell therapy trial targets Hard-to-Treat stomach cancers

NCT ID NCT07406984

Not yet recruiting Disease control Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called IM96 CAR-T for people with advanced stomach or esophageal cancer that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to better attack cancer cells. The main goal is to check safety and side effects, while also seeing if it can shrink tumors or slow the disease. Only 18 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates